Proceedings of the Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2019

Abstract

Conclusion: The data demonstrate a high level of cross-reactivity between birch-specific IgE and IgG4, and allergens from the birch homologous group, which suggests that the significant clinical effect determined previously for both birch and oak exposure may extend to the entire birch homologous group. #2 Dupilumab improved asthma control and health-related quality of life in patients with oral corticosteroid-dependent, severe asthma during the LIBERTY ASTHMA VENTURE study Linda B. Ford1, Klaus F. Rabe2,3, Robert N. Wolfe4, Santiago Quirce5, Megan S. Rice6, Paul Rowe7, Ariel Teper7, Siddhesh Kamat8, Nikhil Amin8, Neil M.H. Graham8, Asif Khan9 1Asthma and Allergy Center, Bellevue, NE, USA; 2LungenClinic Grosshansdorf (member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Grosshansdorf, Germany; 3Christian-Albrechts University (member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Kiel, Germany; 4Cedars-Sinai Medical Center, Los Angeles, CA, USA; 5Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain; 6Sanofi, Cambridge, MA, USA; 7Sanofi, Bridgewater, NJ, USA; 8Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 9Sanofi, Chilly-Mazarin, France Correspondence: Linda B. Ford Allergy Asthma Clin Immunol 2020, 16(Suppl 1):#2 Background: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4/IL-13, key drivers of type 2 inflammation in multiple diseases. Dupilumab was generally well tolerated. #3 Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts Arian Ghassemian1, Michael W. Tsoulis2, Harold Kim1,3 1Division of Clinical Immunology and Allergy, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada; 2Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA; 3Division of Clinical Immunology and Allergy, Department of Medicine, Michael D.DeGroot School of Medicine, McMaster University, Hamilton, ON, Canada Correspondence: Arian Ghassemian Allergy Asthma Clin Immunol 2020, 16(Suppl 1):#3 Background: Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. While there is there is no statistical difference in the magnitude of eosinophil reduction offered by each agent, benralizumab is superior in decreasing peripheral eosinophil counts to 0 cells/µL. *This study was approved by the Hamilton Integrated Research Ethics Board-5437-C. #4 Controlled dander aerosolization in a naturalistic exposure chamber Laura Haya1, Rym Mehri2, Suzanne Kelly1, Bryan Santone1, Edgar Matida2, William H. Yang1 1Red Maple Trials Inc., Ottawa, ON, Canada; 2Carleton University, Ottawa, ON, Canada Correspondence: Laura Haya Allergy Asthma Clin Immunol 2020, 16(Suppl 1):#4 Background: A naturalistic exposure chamber housing two neutered male cats has been developed (Red Maple Trials, Ottawa) to test allergic responses of subjects during controlled exposures to Fel d 1. To improve upon traditional methods of dander aerosolization in which bedding is shaken resulting in transient levels of allergen, we have developed an automated delivery system with adjustable flow, using a modified robotic vacuum cleaner.